These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16885911)

  • 1. The role of prevalence in the diagnosis of prostate cancer.
    Delongchamps NB; Singh A; Haas GP
    Cancer Control; 2006 Jul; 13(3):158-68. PubMed ID: 16885911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era.
    Konety BR; Bird VY; Deorah S; Dahmoush L
    J Urol; 2005 Nov; 174(5):1785-8; discussion 1788. PubMed ID: 16217287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of increasing detection in the rising incidence of prostate cancer.
    Potosky AL; Miller BA; Albertsen PC; Kramer BS
    JAMA; 1995 Feb; 273(7):548-52. PubMed ID: 7530782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adenocarcinoma of the prostate].
    Dvorácek J
    Cas Lek Cesk; 1998 Aug; 137(17):515-21. PubMed ID: 9787503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era.
    Jahn JL; Giovannucci EL; Stampfer MJ
    Int J Cancer; 2015 Dec; 137(12):2795-802. PubMed ID: 25557753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
    Roobol MJ; Grenabo A; Schröder FH; Hugosson J
    J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer.
    Isola J; Auvinen A; Poutiainen M; Kakkola L; Järvinen TA; Määttänen L; Stenman UH; Tammela T; Hakama M; Visakorpi T
    J Urol; 2001 May; 165(5):1569-74. PubMed ID: 11342919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme.
    Gondos A; Krilaviciute A; Smailyte G; Ulys A; Brenner H
    Eur J Cancer; 2015 Aug; 51(12):1630-7. PubMed ID: 26044924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis, management and screening of early localised prostate cancer.
    Selley S; Donovan J; Faulkner A; Coast J; Gillatt D
    Health Technol Assess; 1997; 1(2):i, 1-96. PubMed ID: 9414541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
    Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
    Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families.
    Matikainen MP; Schleutker J; Mörsky P; Kallioniemi OP; Tammela TL
    Clin Cancer Res; 1999 Jun; 5(6):1275-9. PubMed ID: 10389909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of prostate-specific antigen in the chemoprevention of prostate cancer.
    Crawford ED; DeAntoni EP; Ross CA
    J Cell Biochem Suppl; 1996; 25():149-55. PubMed ID: 9027612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden.
    Jonsson H; Holmström B; Duffy SW; Stattin P
    Int J Cancer; 2011 Oct; 129(8):1881-8. PubMed ID: 21154740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Early diagnosis and screening of cancer of the prostate].
    Fendler JP; Perrin P
    Presse Med; 1995 Oct; 24(32):1461-3. PubMed ID: 8545342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy.
    Babaian RJ; Johnston DA; Naccarato W; Ayala A; Bhadkamkar VA; Fritsche HA HA
    J Urol; 2001 Mar; 165(3):757-60. PubMed ID: 11176461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ; Roobol DW; Schröder FH
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dramatic increase in prostate cancer cases by 2021.
    Quon H; Loblaw A; Nam R
    BJU Int; 2011 Dec; 108(11):1734-8. PubMed ID: 21507185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.